SLAS2017 Short Courses
Derivation, Maintenance, and Characterization Techniques for Human iPS Cells Used in Drug Discovery and Disease Modeling
This discussion based course will provide an overview on stem cell biology and the laboratory techniques used to derive and maintain human induced pluripotent stem cells (iPS). Additional topics will include the current state of stem cell research, manual and semi-automated reprogramming and maintenance techniques, and characterization assays and HTS strategies.
Who Should Attend:
- Individuals who desire to understand the technical requirements for deriving, maintaining, characterizing and differentiating human IPS dell lines.
- Scientists and automation specialists with some tissue culture experience but little to no experience in working with ES or iPS cell lines.
- Those interested in developing ips / ips derived screening campaigns.
How You Will Benefit From This Course?
- Gain an understanding of stem cell biology
- Learn how to derive and maintain iPS lines from human dermal fibroblasts
- Learn appropriate iPS/ES characterization assays
- Direct contact with experienced stem cell scientists
- Introduction to Stem Cell Biology
- Derivation and Maintenance of Stem cell lines
- Characterization Techniques
- Automated Stem Cell Processing Systems
David J. Kahler
David Kahler earned his Ph.D. in Molecular Medicine and Immunology from the Medical College of Georgia in the lab of Andrew Mellor. At the New York Stem Cell Foundation, Dr. Kahler served as the Director of the Flow Cytometry Core and Drug Discovery laboratories, and as Director of Laboratory Automation where he developed FCM/FACS based and automated technologies for the derivation, characterization and maintenance of human IPSC lines. Currently he is providing experimental design, assay development and data analysis support to clients of the High Throughput Biology Core Laboratory at the NYU Langone School of Medicine.
Kamal Garcha earned his Ph.D. in the Department of Cellular and Physiological Sciences at the University of British Columbia where he developed a high content/throughput cell based assay to identify small molecules and pathways that influence chondrogenesis. As a post-doctoral fellow, he reprogrammed some of the first iPSCs from patients with bone and cartilage disorders in 2009, and later reprogrammed several lung tumor cell lines. This lead to Dr. Garcha's recruitment as a managing Director for the Canadian Centre for Commercialization of Regenerative Medicine's cell reprogramming and cell line engineering group. Currently, he is Sr. Project Manager at the University Health Network (Toronto), and provides consultative services to biotech and healthcare sectors.